Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/III study of neoadjuvant QL1706 in resectable MSI-H/dMMR colon cancer
CTR20244257Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706 in colon cancer, sponsored by Qilu Pharmaceutical. Started Dec 2024; status: active.
02
Drugs
QL1706
03
Conditions
colon cancer
Beyond the preview
Go deeper on CTR20244257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244257.